Analyst Price Targets — VERX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 9, 2026 1:10 pm | — | Jefferies | $14.00 | $14.93 | TheFly | Vertex price target lowered to $14 from $16 at Jefferies |
| May 8, 2026 1:27 pm | Chris Quintero | Morgan Stanley | $19.00 | $14.56 | TheFly | Vertex price target raised to $19 from $18 at Morgan Stanley |
| May 8, 2026 12:42 pm | — | D.A. Davidson | $15.00 | $14.40 | TheFly | Vertex price target raised to $15 from $13 at DA Davidson |
| May 7, 2026 10:09 pm | Adam Hotchkiss | Goldman Sachs | $21.00 | $14.67 | TheFly | Vertex price target lowered to $21 from $23 at Goldman Sachs |
| April 30, 2026 4:48 pm | — | Morgan Stanley | $18.00 | $12.23 | TheFly | Vertex price target lowered to $18 from $20 at Morgan Stanley |
| February 12, 2026 1:52 pm | — | D.A. Davidson | $13.00 | $12.32 | TheFly | Vertex price target lowered to $13 from $23 at DA Davidson |
| February 12, 2026 1:46 pm | — | BMO Capital | $16.00 | $12.79 | TheFly | Vertex price target lowered to $16 from $22 at BMO Capital |
| February 12, 2026 1:33 pm | Adam Hotchkiss | Goldman Sachs | $23.00 | $12.16 | TheFly | Vertex price target lowered to $23 from $25 at Goldman Sachs |
| February 12, 2026 1:16 pm | — | Morgan Stanley | $20.00 | $12.80 | TheFly | Vertex price target lowered to $20 from $33 at Morgan Stanley |
| February 12, 2026 11:44 am | — | UBS | $25.00 | $12.83 | TheFly | Vertex price target lowered to $25 from $37 at Citizens |
Latest News for VERX
KING OF PRUSSIA, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release second quarter 2026 financial results after the market close on Monday, August 3, 2026. A conference call to discuss the results will be held at 5:00 p.m. Eastern Time that same day.
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other treatment areas, and efforts have been bearing fruit.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VERX.
U.S. House Trading
No House trades found for VERX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.